Tumor stroma as a target in cancer

Current Cancer Drug Targets

Volumn 8, Issue 6, 2008, Pages 447-453

  Ahmed, F ^a   Steele, J C ^a   Herbert, J M J ^a   Steven, N M ^a   Bicknell, R ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Angiogenesis; Anti angiogenesis; Cancer vaccine; Stromal fibroblasts; Stromal macrophages; Tumor endothelial marker; Vascular endothelial growth factor; Vascular targeting

Indexed keywords

ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CANCER VACCINE; COMPLEMENTARY DNA; CYTOTOXIC AGENT; DNA VACCINE; ENDOGLIN; ENDOSIALIN; EXTRA DOMAIN BETA FIBRONECTIN; FIBRONECTIN; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 12; IRINOTECAN; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; OSTEONECTIN; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; ROBO4 PROTEIN; SORAFENIB; SUNITINIB; TENASCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN KINOID VACCINE; VASCULOTROPIN RECEPTOR 2; VIMENTIN;

ADVANCED CANCER; ANGIOGENESIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL TYPE; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DENDRITIC CELL; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; GROWTH INHIBITION; HUMAN; IMMUNIZATION; KIDNEY CANCER; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MACROPHAGE; MELANOMA; MONOTHERAPY; NONHUMAN; POLYMERASE CHAIN REACTION; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; STROMA; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR STROMAL CELL; VASCULAR ENDOTHELIUM;

DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; STROMAL CELLS;

EID: 51349092937     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908785699360     Document Type: Review

References (76)

1. Li, H.; Fan, X.; Houghton, J. Tumor microenvironment: the role of the tumor stroma in cancer. J. Cell. Biochem. 2007, 101, 805-815.
2. Burrows, F. J.; Thorpe, P. E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA 1993, 90, 8996-9000.
3. Covassin, L.; Amigo, J. D.; Suzuki, K.; Teplyuk, V.; Straubhaar, J.; Lawson, N. D. Global analysis of hematopoietic and vascular endothelial gene expression by tissue specific microarray profiling in zebrafish. Dev. Biol. 2006, 299, 551-562.
4. Hirashima, M.; Bernstein, A.; Stanford, W. L.; Rossant, J. Genetrap expression screening to identify endothelial-specific genes. Blood 2004, 104, 711-718.
5. St Croix, B.; Rago, C.; Velculescu, V.; Traverso, G.; Romans, K. E.; Montgomery, E.; Lal, A.; Riggins, G. J.; Lengauer, C.; Vogelstein, B.; Kinzler, K. W. Genes expressed in human tumor endothelium. Science 2000, 289, 1197-1202.
6. Huminiecki, L.; Bicknell, R. In silico cloning of novel endothelial-specific genes. Genome Res. 2000, 10, 1796-1806.
7. Ho, M.; Yang, E.; Matcuk, G.; Deng, D.; Sampas, N.; Tsalenko, A.; Tabibiazar, R.; Zhang, Y.; Chen, M.; Talbi, S.; Ho, Y. D.; Wang, J.; Tsao, P. S.; Ben-Dor, A.; Yakhini, Z.; Bruhn, L.; Quertermous, T. Identification of endothelial cell genes by combined database mining and microarray analysis. Physiol. Genomics 2003, 13, 249-262.
8. Altschul, S. F.; Gish, W.; Miller, W.; Myers, E. W.; Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 1990, 215, 403-410.
9. Huminiecki, L.; Gorn, M.; Suchting, S.; Poulsom, R.; Bicknell, R. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics 2002, 79, 547-552.
10. Seth, P.; Lin, Y.; Hanai, J.; Shivalingappa, V.; Duyao, M. P.; Sukhatme, V. P. Magic roundabout, a tumor endothelial marker: expression and signaling. Biochem. Biophys. Res. Commun. 2005, 332, 533-541.
11. Nanda, A.; St Croix, B. Tumor endothelial markers: new targets for cancer therapy. Curr. Opin. Oncol. 2004, 16, 44-49.
12. Carson-Walter, E. B.; Watkins, D. N.; Nanda, A.; Vogelstein, B.; Kinzler, K. W.; St Croix, B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001, 61, 6649-6655.
13. Rettig, W. J.; Garin-Chesa, P.; Healey, J. H.; Su, S. L.; Jaffe, E. A.; Old, L. J. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc. Natl. Acad. Sci. USA 1992, 89, 10832-10836.
14. MacFadyen, J.; Savage, K.; Wienke, D.; Isacke, C. M. Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development. Gene Expr. Patterns 2007, 7, 363-369.
15. MacFadyen, J. R.; Haworth, O.; Roberston, D.; Hardie, D.; Webster, M. T.; Morris, H. R.; Panico, M.; Sutton-Smith, M.; Dell, A.; van der Geer, P.; Wienke, D.; Buckley, C. D.; Isacke, C. M. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett. 2005, 579, 2569-2575.
16. Nanda, A.; Karim, B.; Peng, Z.; Liu, G.; Qiu, W.; Gan, C.; Vogelstein, B.; St Croix, B.; Kinzler, K. W.; Huso, D. L. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc. Natl. Acad. Sci. USA 2006, 103, 3351-3356.
17. Park, K. W.; Morrison, C. M.; Sorensen, L. K.; Jones, C. A.; Rao, Y.; Chien, C. B.; Wu, J. Y.; Urness, L. D.; Li, D. Y. Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev. Biol. 2003, 261, 251-267.
18. Wang, J. M.; Kumar, S.; Pye, D.; van Agthoven, A. J.; Krupinski, J.; Hunter, R. D. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int. J. Cancer 1993, 54, 363-370.
19. Burrows, F. J.; Derbyshire, E. J.; Tazzari, P. L.; Amlot, P.; Gazdar, A. F.; King, S. W.; Letarte, M.; Vitetta, E. S.; Thorpe, P. E. Upregulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res. 1995, 1, 1623-1634.
20. Lee, S. H.; Mizutani, N.; Mizutani, M.; Luo, Y.; Zhou, H.; Kaplan, C.; Kim, S. W.; Xiang, R.; Reisfeld, R. A. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol. Immunother. 2006, 55, 1565-1574.
21. Tan, G. H.; Wei, Y. Q.; Tian, L.; Zhao, X.; Yang, L.; Li, J.; He, Q. M.; Wu, Y.; Wen, Y. J.; Yi, T.; Ding, Z. Y.; Kan, B.; Mao, Y. Q.; Deng, H. X.; Li, H. L.; Zhou, C. H.; Fu, C. H.; Xiao, F.; Zhang, X. W. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur. J. Immunol. 2004, 34, 2012-2021.
22. Jiao, J. G.; Li, Y. N.; Wang, H.; Liu, Q.; Cao, J. X.; Bai, R. Z.; Huang, F. Y. A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models. Dig. Liver Dis. 2006, 38, 578-587.
23. Luo, Y.; Wen, Y. J.; Ding, Z. Y.; Fu, C. H.; Wu, Y.; Liu, J. Y.; Li, Q.; He, Q. M.; Zhao, X.; Jiang, Y.; Li, J.; Deng, H. X.; Kang, B.; Mao, Y. Q.; Wei, Y. Q. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Clin. Cancer Res. 2006, 12, 1813-1819.
24. Ramage, J. M.; Metheringham, R.; Conn, A.; Spendlove, I.; Moss, R. S.; Patton, D. T.; Murray, J. C.; Rees, R. C.; Durrant, L. G. Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2. Int. J. Cancer 2004, 110, 245-250.
25. Mor-Vaknin, N.; Punturieri, A.; Sitwala, K.; Markovitz, D. M. Vimentin is secreted by activated macrophages. Nat. Cell Biol. 2003, 5, 59-63.
26. van Beijnum, J. R.; Dings, R. P.; van der Linden, E.; Zwaans, B. M.; Ramaekers, F. C.; Mayo, K. H.; Griffioen, A. W. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006, 108, 2339-2348.
27. Ikuta, Y.; Nakatsura, T.; Kageshita, T.; Fukushima, S.; Ito, S.; Wakamatsu, K.; Baba, H.; Nishimura, Y. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin. Cancer Res. 2005, 11, 8079-8088.
28. Schittenhelm, J.; Mittelbronn, M.; Roser, F.; Tatagiba, M.; Mawrin, C.; Bornemann, A. Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas. Neuropathol. Appl. Neurobiol. 2006, 32, 525-531.
29. Brekken, R. A.; Huang, X.; King, S. W.; Thorpe, P. E. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 1998, 58, 1952-1959.
30. Li, Y.; Wang, M. N.; Li, H.; King, K. D.; Bassi, R.; Sun, H.; Santiago, A.; Hooper, A. T.; Bohlen, P.; Hicklin, D. J. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 2002, 195, 1575-1584.
31. Niederman, T. M.; Ghogawala, Z.; Carter, B. S.; Tompkins, H. S.; Russell, M. M.; Mulligan, R. C. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc. Natl. Acad. Sci. USA 2002, 99, 7009-7014.
32. Rad, F. H.; Le Buanec, H.; Paturance, S.; Larcier, P.; Genne, P.; Ryffel, B.; Bensussan, A.; Bizzini, B.; Gallo, R. C.; Zagury, D.; Uzan, G. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc. Natl. Acad. Sci. USA 2007, 104, 2837-2842.
33. Hou, J. M.; Liu, J. Y.; Yang, L.; Zhao, X.; Tian, L.; Ding, Z. Y.; Wen, Y. J.; Niu, T.; Xiao, F.; Lou, Y. Y.; Tan, G. H.; Deng, H. X.; Li, J.; Yang, J. L.; Mao, Y. Q.; Kan, B.; Wu, Y.; Li, Q.; Wei, Y. Q. Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Oncology 2005, 69, 81-87.
34. Liu, J. Y.; Wei, Y. Q.; Yang, L.; Zhao, X.; Tian, L.; Hou, J. M.; Niu, T.; Liu, F.; Jiang, Y.; Hu, B.; Wu, Y.; Su, J. M.; Lou, Y. Y.; He, Q. M.; Wen, Y. J.; Yang, J. L.; Kan, B.; Mao, Y. Q.; Luo, F.; Peng, F. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003, 102, 1815-1823.
35. Keke, F.; Hongyang, Z.; Hui, Q.; Jixiao, L.; Jian, C. A combination of flk1-based DNA vaccine and an immunomodulatory gene (IL-12) in the treatment of murine cancer. Cancer Biother. Radiopharm. 2004, 19, 649-657.
36. Dong, Y.; Qian, J.; Ibrahim, R.; Berzofsky, J. A.; Khleif, S. N. Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J. Immunother. 2006, 29, 32-40.
37. Wada, S.; Tsunoda, T.; Baba, T.; Primus, F. J.; Kuwano, H.; Shibuya, M.; Tahara, H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005, 65, 4939-4946.
38. Ishizaki, H.; Tsunoda, T.; Wada, S.; Yamauchi, M.; Shibuya, M.; Tahara, H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin. Cancer Res. 2006, 12, 5841-5849.
39. Reisfeld, R. A.; Niethammer, A. G.; Luo, Y.; Xiang, R. DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis. Int. Arch. Allergy Immunol. 2004, 133, 295-304.
40. Reisfeld, R. A.; Niethammer, A. G.; Luo, Y.; Xiang, R. DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis. Immunol. Rev. 2004, 199, 181-190.
41. Manning, E. A.; Ullman, J. G.; Leatherman, J. M.; Asquith, J. M.; Hansen, T. R.; Armstrong, T. D.; Hicklin, D. J.; Jaffee, E. M.; Emens, L. A. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 2007, 13, 3951-3959.
42. Fricke, I.; Mirza, N.; Dupont, J.; Lockhart, C.; Jackson, A.; Lee, J. H.; Sosman, J. A.; Gabrilovich, D. I. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 2007, 13, 4840-4848.
43. Kim, K. J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362, 841-844.
44. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
45. Giantonio, B. J.; Catalano, P. J.; Meropol, N. J.; O'Dwyer, P. J.; Mitchell, E. P.; Alberts, S. R.; Schwartz, M. A.; Benson, A. B., 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007, 25, 1539-1544.
46. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7, 987-989.
47. Willett, C. G.; Boucher, Y.; di Tomaso, E.; Duda, D. G.; Munn, L. L.; Tong, R. T.; Chung, D. C.; Sahani, D. V.; Kalva, S. P.; Kozin, S. V.; Mino, M.; Cohen, K. S.; Scadden, D. T.; Hartford, A. C.; Fischman, A. J.; Clark, J. W.; Ryan, D. P.; Zhu, A. X.; Blaszkowsky, L. S.; Chen, H. X.; Shellito, P. C.; Lauwers, G. Y.; Jain, R. K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10, 145-147.
48. Morabito, A.; De Maio, E.; Di Maio, M.; Normanno, N.; Perrone, F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006, 11, 753-764.
49. Motzer, R. J.; Hoosen, S.; Bello, C. L.; Christensen, J. G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs 2006, 15, 553-561.
50. Roskoski, R., Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 2007, 356, 323-328.
51. Chow, L. Q.; Eckhardt, S. G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 2007, 25, 884-896.
52. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R. A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006, 5, 835-844.
53. Verheul, H. M.; Pinedo, H. M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer 2007, 7, 475-485.
54. Carmeliet, P.; Moons, L.; Luttun, A.; Vincenti, V.; Compernolle, V.; De Mol, M.; Wu, Y.; Bono, F.; Devy, L.; Beck, H.; Scholz, D.; Acker, T.; DiPalma, T.; Dewerchin, M.; Noel, A.; Stalmans, I.; Barra, A.; Blacher, S.; Vandendriessche, T.; Ponten, A.; Eriksson, U.; Plate, K. H.; Foidart, J. M.; Schaper, W.; Charnock-Jones, D. S.; Hicklin, D. J.; Herbert, J. M.; Collen, D.; Persico, M. G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7, 575-583.
55. Hiratsuka, S.; Maru, Y.; Okada, A.; Seiki, M.; Noda, T.; Shibuya, M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 2001, 61, 1207-1213.
56. Fischer, C.; Jonckx, B.; Mazzone, M.; Zacchigna, S.; Loges, S.; Pattarini, L.; Chorianopoulos, E.; Liesenborghs, L.; Koch, M.; De Mol, M.; Autiero, M.; Wyns, S.; Plaisance, S.; Moons, L.; van Rooijen, N.; Giacca, M.; Stassen, J. M.; Dewerchin, M.; Collen, D.; Carmeliet, P. Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels. Cell 2007, 131, 463-475.
57. Jain, R. K.; Xu, L. alphaPlGF: A New Kid on the Antiangiogenesis Block. Cell 2007, 131, 443-445.
58. Zardi, L.; Carnemolla, B.; Siri, A.; Petersen, T. E.; Paolella, G.; Sebastio, G.; Baralle, F. E. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 1987, 6, 2337-2342.
59. Castellani, P.; Viale, G.; Dorcaratto, A.; Nicolo, G.; Kaczmarek, J.; Querze, G.; Zardi, L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 1994, 59, 612-618.
60. Carnemolla, B.; Balza, E.; Siri, A.; Zardi, L.; Nicotra, M. R.; Bigotti, A.; Natali, P. G. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell. Biol. 1989, 108, 1139-1148.
61. Viti, F.; Tarli, L.; Giovannoni, L.; Zardi, L.; Neri, D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 1999, 59, 347-352.
62. Tarli, L.; Balza, E.; Viti, F.; Borsi, L.; Castellani, P.; Berndorff, D.; Dinkelborg, L.; Neri, D.; Zardi, L. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999, 94, 192-198.
63. Demartis, S.; Tarli, L.; Borsi, L.; Zardi, L.; Neri, D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur. J. Nucl. Med. 2001, 28, 534-539.
64. Borsi, L.; Balza, E.; Bestagno, M.; Castellani, P.; Carnemolla, B.; Biro, A.; Leprini, A.; Sepulveda, J.; Burrone, O.; Neri, D.; Zardi, L. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 2002, 102, 75-85.
65. Santimaria, M.; Moscatelli, G.; Viale, G. L.; Giovannoni, L.; Neri, G.; Viti, F.; Leprini, A.; Borsi, L.; Castellani, P.; Zardi, L.; Neri, D.; Riva, P. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 2003, 9, 571-579.
66. Birchler, M. T.; Thuerl, C.; Schmid, D.; Neri, D.; Waibel, R.; Schubiger, A.; Stoeckli, S. J.; Schmid, S.; Goerres, G. W. Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment. Otolaryngol. Head Neck Surg. 2007, 136, 543-548.
67. Chiquet-Ehrismann, R. Tenascins. Int. J. Biochem. Cell Biol. 2004, 36, 986-990.
68. Carnemolla, B.; Castellani, P.; Ponassi, M.; Borsi, L.; Urbini, S.; Nicolo, G.; Dorcaratto, A.; Viale, G.; Winter, G.; Neri, D.; Zardi, L. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am. J. Pathol. 1999, 154, 1345-1352.
69. Borsi, L.; Carnemolla, B.; Nicolo, G.; Spina, B.; Tanara, G.; Zardi, L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer 1992, 52, 688-692.
70. Degen, M.; Brellier, F.; Kain, R.; Ruiz, C.; Terracciano, L.; Orend, G.; Chiquet-Ehrismann, R. Tenascin-W Is a Novel Marker for Activated Tumor Stroma in Low-grade Human Breast Cancer and Influences Cell Behavior. Cancer Res. 2007, 67, 9169-9179.
71. Loeffler, M.; Kruger, J. A.; Niethammer, A. G.; Reisfeld, R. A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 2006, 116, 1955-1962.
72. Fassnacht, M.; Lee, J.; Milazzo, C.; Boczkowski, D.; Su, Z.; Nair, S.; Gilboa, E. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin. Cancer Res. 2005, 11, 5566-5571.
73. Leek, R. D.; Harris, A. L. Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia 2002, 7, 177-189.
74. Lewis, C. E.; Pollard, J. W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66, 605-612.
75. Aharinejad, S.; Paulus, P.; Sioud, M.; Hofmann, M.; Zins, K.; Schafer, R.; Stanley, E. R.; Abraham, D. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 2004, 64, 5378-5384.
76. Aharinejad, S.; Sioud, M.; Lucas, T.; Abraham, D. Target validation using RNA interference in solid tumors. Methods Mol. Biol. 2007, 361, 227-238.